Evogene (NASDAQ:EVGN) Stock Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Evogene Ltd. (NASDAQ:EVGN)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.72 and traded as low as $1.00. Evogene shares last traded at $1.01, with a volume of 11,485 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a report on Friday, March 7th. StockNews.com initiated coverage on shares of Evogene in a research note on Friday. They set a “sell” rating on the stock.

Evogene Trading Down 5.4 %

The stock has a market cap of $5.42 million, a PE ratio of -0.23 and a beta of 1.37. The business has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $1.72.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period in the prior year, the firm earned ($1.30) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.